The present disclosure relates to a pharmaceutical combination, e.g. a product, comprising a combination of (i) a Mdm2 inhibitor and (ii) a BRAF inhibitor, or a pharmaceutically acceptable salt thereof, respectively, which are jointly active in the treatment of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, data carrier and related disclosure embodiments. In addition, the disclosure relates to the use of Mdm2 inhibitor in the treatment of colorectal cancer.本發明係關於一種醫藥組合(例如一種產品),其包含(i)Mdm2抑制劑與(ii)BRAF抑制劑或其各別醫藥學上可接受之鹽的組合,其在治療增生性疾病中為共同有效。本發明亦關於相應醫藥調配物、用途、方法、組合、資料載體及相關發明實施例。此外,本發明係關於Mdm2抑制劑治療結腸直腸癌之用途。
